Compare Omnicom Group Inc. (OMC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Omnicom Group Inc. trades at $78.55 (market cap $22.26B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Omnicom Group Inc. is far larger — about 12× Recursion Pharmaceuticals Inc's market cap, and Omnicom Group Inc. pays a 3.94% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| OMC | RXRX | |
|---|---|---|
Market Cap | $22.26B | $1.86B |
Sector | Media | Health |
52-Week High | $88.94 | $6.79 |
52-Week Low | $67.27 | $2.84 |
Enterprise Value | $30.33B | $1.38B |
Dividend Yield | 3.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $81.13, down 1.8% on the day, with a bearish technical outlook and mixed quarterly earnings performance. The company reported strong revenue growth to $17.27 billion in 2025 but posted a net loss of $54.5 million due to acquisition costs. Analyst consensus remains cautious with a 'Hold' rating despite a $96.50 price target representing 19% upside potential. Recent leadership transitions and media agency consolidation signal strategic repositioning amid challenging market conditions.
OMC presents a value opportunity with attractive valuation multiples (P/S: 0.91x, P/B: 2.3x) and a 4% dividend yield, but faces integration risks from the Interpublic acquisition and margin pressure. The stock's near-term trajectory depends on successful cost synergies and organic growth acceleration beyond current 6.1% levels. Debt levels have increased substantially post-acquisition, requiring careful monitoring of cash flow generation.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
